Viking Therapeutics, Inc.
No SEC Form 4 filings for $VKTX in the last 30 days.
Truist Financial began coverage of Viking Therapeutics (VKTX) with a “buy” rating and an $83.00 price target, implying 159.5% upside from the prior close, according to the firm. Other analysts set targets from $95 to $102 and ratings ranging from “buy” to “sell.” VKTX shares traded at $31.99 midweek; it reported Q1 EPS of ($1.37), missing the ($1.01) consensus.
Polymarket traders and analysts are focusing on Viking Therapeutics (VKTX) as an obesity M&A target, citing an estimated 38.5% implied acquisition probability before 2027. The company has no revenue and a ~$3.59B market cap; shares closed at $30.89 on May 22, 2026. Analysts’ mean target is $92.33. Viking’s oral VK2735 showed up to 12.2% weight loss at 13 weeks, and Phase 3 VANQUISH-1 is fully enrolled with 4,500+ patients. Potential buyers mentioned include Eli Lilly, Pfizer, and Novo Nordisk.
The article argues that obesity-drug demand could drive growth in 2026 and highlights two stocks. Viking Therapeutics (VKTX) is advancing VK-2735, a dual GLP-1/GIP agonist, in phase 3; it expects oral phase 3 later this year and phase 3 data in Q3. AbbVie (ABBV) reported 12% revenue growth to $15B in the latest quarter and is developing ABBV-295, an amylin analog, with phase 1 weight loss of >7% to >9% in 12–13 weeks.
